Interleukin-2 shows high adjuvanticity for an inactivated vaccine against duck Tembusu virus disease
Currently, the widely used vaccine against duck Tembusu virus (DTMUV) disease is inactivated vaccine which, however, facing the limits of large inoculation dose, short immunization period, and incomplete effectiveness. Access to efficient adjuvants aiding for DTMUV inactivated vaccine seems to be of...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | Poultry Science |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0032579120305605 |
id |
doaj-9231b13e8d7e46a09163f1d4bdfa28c8 |
---|---|
record_format |
Article |
spelling |
doaj-9231b13e8d7e46a09163f1d4bdfa28c82020-11-27T04:16:27ZengElsevierPoultry Science0032-57912020-12-01991264546461Interleukin-2 shows high adjuvanticity for an inactivated vaccine against duck Tembusu virus diseaseXintao Gao0Xiao Ren1Shan Zhang2Haozhi Song3Xiaoyu Guo4Hong Jia5Ting Xin6Yitong Jiang7Zhifang Zhang8Shaohua Hou9Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China; Beijing Zhongnong Bioengineering Co., Ltd., Beijing 100193, ChinaInstitute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, China; Beijing Zhongnong Bioengineering Co., Ltd., Beijing 100193, ChinaInstitute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, ChinaBiotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, ChinaInstitute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, ChinaInstitute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, ChinaInstitute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, ChinaInstitute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, ChinaBiotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China; Corresponding authors:Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, China; Corresponding authors:Currently, the widely used vaccine against duck Tembusu virus (DTMUV) disease is inactivated vaccine which, however, facing the limits of large inoculation dose, short immunization period, and incomplete effectiveness. Access to efficient adjuvants aiding for DTMUV inactivated vaccine seems to be of critical importance. Interleukin-2 (IL-2) was reported to induce a persistent expansion of effector T cells and could be a promising molecular adjuvant for many kinds of vaccines. In this study, the efficacy of duck interleukin (dIL)-2 as an adjuvant for a DTMUV inactivated vaccine was evaluated. Fifty-five Pekin ducks were divided into 5 groups and intramuscularly administered with 5 batches of vaccines at 42 D (A: DTUMV + dIL-2; B: 1/2DTUMV + dIL-2; C: DTUMV; D: 1/2DTUMV and E: PBS), respectively, and received the second vaccination 2 wk later. Fifty-six days after immunization, 6 ducks from each group were randomly selected to conduct a challenge protection test. Antibody titers and cytokine responses were detected to assess humoral and cellular immune responses in serum of inoculated ducks by hemagglutination inhibition and ELISA, respectively; virus isolation and RT-PCR method were used in immunity protective test. Our results showed that dIL-2 exerted an enhanced effect on the vaccine while reducing the dose of inoculated antigen highlighting high adjuvanticity of IL-2. The vaccines supplemented with IL-2 induced a higher level of antibodies and higher percentage of inhibition values than inactivated vaccines without IL-2 to a significant extent. The production level of IFN-α, IFN-γ, and IL-6 genes were elevated, enhancing both humoral and cellular responses. Furthermore, it provided higher protection after virus challenge. Therefore, IL-2 can be considered as a potential adjuvant for inactivated vaccine against DTMUV disease.http://www.sciencedirect.com/science/article/pii/S0032579120305605duck Tembusu virusdIL-2adjuvantinactivated vaccinedose |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xintao Gao Xiao Ren Shan Zhang Haozhi Song Xiaoyu Guo Hong Jia Ting Xin Yitong Jiang Zhifang Zhang Shaohua Hou |
spellingShingle |
Xintao Gao Xiao Ren Shan Zhang Haozhi Song Xiaoyu Guo Hong Jia Ting Xin Yitong Jiang Zhifang Zhang Shaohua Hou Interleukin-2 shows high adjuvanticity for an inactivated vaccine against duck Tembusu virus disease Poultry Science duck Tembusu virus dIL-2 adjuvant inactivated vaccine dose |
author_facet |
Xintao Gao Xiao Ren Shan Zhang Haozhi Song Xiaoyu Guo Hong Jia Ting Xin Yitong Jiang Zhifang Zhang Shaohua Hou |
author_sort |
Xintao Gao |
title |
Interleukin-2 shows high adjuvanticity for an inactivated vaccine against duck Tembusu virus disease |
title_short |
Interleukin-2 shows high adjuvanticity for an inactivated vaccine against duck Tembusu virus disease |
title_full |
Interleukin-2 shows high adjuvanticity for an inactivated vaccine against duck Tembusu virus disease |
title_fullStr |
Interleukin-2 shows high adjuvanticity for an inactivated vaccine against duck Tembusu virus disease |
title_full_unstemmed |
Interleukin-2 shows high adjuvanticity for an inactivated vaccine against duck Tembusu virus disease |
title_sort |
interleukin-2 shows high adjuvanticity for an inactivated vaccine against duck tembusu virus disease |
publisher |
Elsevier |
series |
Poultry Science |
issn |
0032-5791 |
publishDate |
2020-12-01 |
description |
Currently, the widely used vaccine against duck Tembusu virus (DTMUV) disease is inactivated vaccine which, however, facing the limits of large inoculation dose, short immunization period, and incomplete effectiveness. Access to efficient adjuvants aiding for DTMUV inactivated vaccine seems to be of critical importance. Interleukin-2 (IL-2) was reported to induce a persistent expansion of effector T cells and could be a promising molecular adjuvant for many kinds of vaccines. In this study, the efficacy of duck interleukin (dIL)-2 as an adjuvant for a DTMUV inactivated vaccine was evaluated. Fifty-five Pekin ducks were divided into 5 groups and intramuscularly administered with 5 batches of vaccines at 42 D (A: DTUMV + dIL-2; B: 1/2DTUMV + dIL-2; C: DTUMV; D: 1/2DTUMV and E: PBS), respectively, and received the second vaccination 2 wk later. Fifty-six days after immunization, 6 ducks from each group were randomly selected to conduct a challenge protection test. Antibody titers and cytokine responses were detected to assess humoral and cellular immune responses in serum of inoculated ducks by hemagglutination inhibition and ELISA, respectively; virus isolation and RT-PCR method were used in immunity protective test. Our results showed that dIL-2 exerted an enhanced effect on the vaccine while reducing the dose of inoculated antigen highlighting high adjuvanticity of IL-2. The vaccines supplemented with IL-2 induced a higher level of antibodies and higher percentage of inhibition values than inactivated vaccines without IL-2 to a significant extent. The production level of IFN-α, IFN-γ, and IL-6 genes were elevated, enhancing both humoral and cellular responses. Furthermore, it provided higher protection after virus challenge. Therefore, IL-2 can be considered as a potential adjuvant for inactivated vaccine against DTMUV disease. |
topic |
duck Tembusu virus dIL-2 adjuvant inactivated vaccine dose |
url |
http://www.sciencedirect.com/science/article/pii/S0032579120305605 |
work_keys_str_mv |
AT xintaogao interleukin2showshighadjuvanticityforaninactivatedvaccineagainstducktembusuvirusdisease AT xiaoren interleukin2showshighadjuvanticityforaninactivatedvaccineagainstducktembusuvirusdisease AT shanzhang interleukin2showshighadjuvanticityforaninactivatedvaccineagainstducktembusuvirusdisease AT haozhisong interleukin2showshighadjuvanticityforaninactivatedvaccineagainstducktembusuvirusdisease AT xiaoyuguo interleukin2showshighadjuvanticityforaninactivatedvaccineagainstducktembusuvirusdisease AT hongjia interleukin2showshighadjuvanticityforaninactivatedvaccineagainstducktembusuvirusdisease AT tingxin interleukin2showshighadjuvanticityforaninactivatedvaccineagainstducktembusuvirusdisease AT yitongjiang interleukin2showshighadjuvanticityforaninactivatedvaccineagainstducktembusuvirusdisease AT zhifangzhang interleukin2showshighadjuvanticityforaninactivatedvaccineagainstducktembusuvirusdisease AT shaohuahou interleukin2showshighadjuvanticityforaninactivatedvaccineagainstducktembusuvirusdisease |
_version_ |
1724414377697738752 |